Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia (SALACIA)

This study has been terminated.
(Recruitment challenges and results of interim futility analysis, which showed less than likely to achieve primary endpoint goal-length of hospital stay.)
Information provided by (Responsible Party):
Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier:
First received: October 22, 2010
Last updated: May 6, 2013
Last verified: May 2013

The purpose of this study is to determine if hospitalized patients with symptomatic hyponatremia treated with tolvaptan are in the hospital for less time than patients treated with fluid restriction. The study will also test if tolvaptan is better than fluid restriction in treating the symptoms of hyponatremia in hospitalized patients.

Condition Intervention Phase
Dilutional Hyponatremia
Inappropriate ADH Syndrome
Drug: tolvaptan
Other: Fluid Restriction
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia

Resource links provided by NLM:

Further study details as provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:

Primary Outcome Measures:
  • Length of Hospital Stay [ Time Frame: 45 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • CGI-S Score [ Time Frame: 48 hours ] [ Designated as safety issue: No ]
    Change from baseline in Clinical Global Impression-Severity(CGI-S) of hyponatremia symptoms.

  • CGI-S Score [ Time Frame: 24 and 72 hours ] [ Designated as safety issue: No ]
    Change from baseline in Clinical Global Impression-Severity(CGI-S) of hyponatremia symptoms.

  • CGI-I score [ Time Frame: 48 hours ] [ Designated as safety issue: No ]
    Clinical Global Impression - Improvement(CGI-I)score of hyponatremia symptoms.

  • Serum Sodium Concentration [ Time Frame: 72 hours ] [ Designated as safety issue: No ]
    Change from baseline in serum sodium concentration(24 hour AUC).

  • Time to 2-point improvement in CGI-S score [ Time Frame: 7 days ] [ Designated as safety issue: No ]
  • Percentage of responders [ Time Frame: 48 hours ] [ Designated as safety issue: No ]
    Clinical Global Impression-Improvement (CGI-I) score improved to a score of 1 or 2.

  • Rescue Therapy [ Time Frame: 7 days ] [ Designated as safety issue: No ]
    Percentage of subjects requiring rescue therapy for hyponatremia.

Enrollment: 124
Study Start Date: October 2010
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tolvaptan 15-60mg
Oral tablet without fluid restriction. After the initial dose, daily dose may be titrated based on response.
Drug: tolvaptan
15 mg titrated to 30 mg then 60 mg once daily as oral tablet for up to 7 days based on response.
Other Names:
  • OPC-41061
  • OPC-156
Active Comparator: Fluid Restriction
Placebo tablet with prescribed fluid restriction. After the initial dose, level of fluid restriction may titrated based response.
Other: Fluid Restriction
Placebo tablet once daily with prescribed daily fluid intake of 1500 mL, then intensifying to 2 lower volumes of fluid intake for up to 7 days based on response.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Hyponatremia in clinically euvolemic or hypervolemic states, defined as serum sodium < 130 mEq/L prior to randomization
  • Clinically significant symptoms of hyponatremia, defined as a CGI-S score between 3-6, inclusive
  • Female subjects of child bearing potential who agree to remain abstinent or to practice double-barrier forms of birth control from screening through 30 days following first dose on IMP

Exclusion Criteria:

  • Women who are pregnant or breast feeding, and females of childbearing potential who are not using acceptable contraceptive methods (such as barrier contraceptives or methods that result in a failure rate of less than 1%)
  • Hyponatremia in hypovolemic states, defined as the presence of clinical and historical evidence of extracellular fluid volume depletion, including but not limited to skin turgor, orthostatic changes in blood pressure or heart rate, dry mucous membranes, or a response to IV saline challenge
  • Subjects who are likely to require prolonged hospitalization for reasons other than hyponatremia, eg. new femoral fracture, surgeries requiring extended recovery
  • Recent prior treatment for hyponatremia: hypertonic saline (including normal saline challenge) (within 8 hours of baseline) or urea, lithium, demeclocycline, conivaptan or tolvaptan (within 4 days of baseline). Includes any treatment, other than fluid restriction for the purpose of increasing serum sodium.
  • Hyponatremia symptoms of a severity (eg, CGI = 7) such that they require immediate intervention with hypertonic saline; or are expected to require such therapy within 48 hours
  • Causes of neurological symptoms which are attributable to psychological (psychosis), structural (dementia of the Alzheimer's type, stroke, transient ischemic attack, multi-infarct dementia) or other metabolic causes (eg. hyper- or hypo-: oxemia, glycemia, calcemia, ammonemia, etc)
  • Acute and transient hyponatremia associated with head trauma or severe neurological injury (eg. stroke, subdural hematoma)or the use of recreational drugs.
  • History of hyponatremia known to be due to severe, untreated hypothyroidism/adrenal insufficiency
  • Subjects with psychogenic polydipsia
  • Systolic arterial blood pressure < 90 mmHg at screening
  • History of hypersensitivity and/or idiosyncratic reaction to benzazepine or benzazepine derivatives (such as benazepril), or tolvaptan
  • History of drug or medication abuse within the 3 months prior to screening, or current alcohol abuse
  • Uncontrolled diabetes mellitus defined as glucose > 300 mg/dL [16.7 mmol/L]
  • Current urinary tract obstruction (eg, obstructive benign prostatic hypertrophy)
  • Current condition of anuria
  • Serum creatinine > 3.5 mg/dL at screening
  • Terminally ill or moribund condition with little chance of short-term (eg, 30 day) survival
  • Subjects whose hyponatremia is the result of any medication that can safely be withdrawn (examples of drugs often not withdrawn include: anticonvulsants [eg, carbamazepine] and antipsychotics [eg, haloperidol])
  • Patients receiving DDAVP within 2 days of screening
  • Patients with history of active variceal bleeding within the past 30 days, without prior approval from sponsor medical monitor
  • Participation in another investigational drug trial within the past 30 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01227512

  Hide Study Locations
United States, Alabama
Otsuka Investigational Site
Birmingham, Alabama, United States, 35242
Otsuka Investigational Site
Birmingham, Alabama, United States, 35216
Otsuka Investigational Site
Mobile, Alabama, United States, 36608
United States, California
Otsuka Investigational Site
Azusa, California, United States, 91702
Otsuka Investigational Site
Banning, California, United States, 92220
Otsuka Investigational Site
Culver City, California, United States, 90232
Otsuka Investigational Site
Fountain Valley, California, United States, 92708
Otsuka Investigational Site
Los Angeles, California, United States, 90025
Otsuka Investigational Site
Los Angeles, California, United States, 90033
Otsuka Investigational Site
Northridge, California, United States, 91324
Otuska Investigational Site
Orange, California, United States, 92868
Otsuka Investigational Site
Yorba Linda, California, United States, 92886
United States, Colorado
Otsuka Investigational Site
Denver, Colorado, United States, 80210
United States, District of Columbia
Otsuka Investigational Site
Washington, District of Columbia, United States, 20010
United States, Florida
Otsuka Investigational Site
Jacksonville, Florida, United States, 32216
Otsuka Investigational Site
Jacksonville, Florida, United States, 32207
Otsuka Investigational Site
Jacksonville, Florida, United States, 32209
Otsuka Investigational Site
Orlando, Florida, United States, 32803
Otsuka Investigational Site
Port Charlotte, Florida, United States, 33952
United States, Georgia
Otsuka Investigational Site
Savannah, Georgia, United States, 31405
United States, Kentucky
Otsuka Investigational Site
Elizabethtown, Kentucky, United States, 42701
United States, Maryland
Otsuka Investigational Site
Baltimore, Maryland, United States, 21215
United States, Massachusetts
Otsuka Investigational Site
Springfield, Massachusetts, United States, 01107
United States, Michigan
Otsuka Investigational Site
Saginaw, Michigan, United States, 48602
Otsuka Investigational Site
Southfield, Michigan, United States, 48075
United States, Minnesota
Otsuka Investigational Site
Minneapolis, Minnesota, United States, 55455
Otsuka Investigational Site
Rochester, Minnesota, United States, 55905
United States, Mississippi
Otsuka Investigational Site
Jackson, Mississippi, United States, 39216
United States, Missouri
Otsuka Investigational Site
St. Louis, Missouri, United States, 63110
United States, Nebraska
Otsuka Investigational Site
Grand Island, Nebraska, United States, 68803
Otsuka Investigational Site
Omaha, Nebraska, United States, 68131
United States, New Jersey
Otsuka Investigational Site
Haddon Heights, New Jersey, United States, 08035
Otsuka Investigational Site
Newark, New Jersey, United States, 07103
United States, New York
Otsuka Investigational Site
Bronx, New York, United States, 10461
Otsuka Investigational Site
Buffalo, New York, United States, 14215
Otsuka Investigational Site
Buffalo, New York, United States, 14203
Otsuka Investigational Site
Jamaica, New York, United States, 11418
Otsuka Investigational Site
New York, New York, United States, 10032
United States, Ohio
Otsuka Investigational Site
Cincinnati, Ohio, United States, 45267
Otsuka Investigational Site
Cleveland, Ohio, United States, 44195
Otsuka Investigational Site
Columbus, Ohio, United States, 43212
Otsuka Investigational Site
Fairfield, Ohio, United States, 45014
Otsuka Investigational Site
Toledo, Ohio, United States, 43560
United States, Oklahoma
Otsuka Investigational Site
Oklahoma City, Oklahoma, United States, 73120
United States, Pennsylvania
Otsuka Investigational Site
Bethleham, Pennsylvania, United States, 18017
Otsuka Investigational Site
Philadelphia, Pennsylvania, United States, 19140
Otsuka Investigational Site
Philadelphia, Pennsylvania, United States, 19102
Otsuka Investigational Site
West Reading, Pennsylvania, United States, 19611
United States, Rhode Island
Otsuka Investigational Site
Providence, Rhode Island, United States, 02903
United States, Texas
Otsuka Investigational Site
Galveston, Texas, United States, 77555
Otsuka Investigational Site
Houston, Texas, United States, 77030
Otsuka Investigational Site
Mission, Texas, United States, 78572
Otsuka Investigational Site
San Antonio, Texas, United States, 78205
Otsuka Investigational Site
San Antonio, Texas, United States, 78229
United States, Virginia
Otsuka Investigational Site
Fairfax, Virginia, United States, 22030
United States, Wisconsin
Otsuka Investigational Site
Madison, Wisconsin, United States, 53705
Sponsors and Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study Director: Ann Dandurand, MD Otsuka Pharmaceutical Development & Commercialization, Inc.
  More Information

No publications provided

Responsible Party: Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier: NCT01227512     History of Changes
Other Study ID Numbers: 156-08-275
Study First Received: October 22, 2010
Last Updated: May 6, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:
Dilutional Hyponatremia
Euvolemic Hyponatremia
Hypervolemic Hyponatremia
Fluid Restriction

Additional relevant MeSH terms:
Inappropriate ADH Syndrome
Water-Electrolyte Imbalance
Metabolic Diseases
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on September 18, 2014